BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
5/20/2019 9:05:36 AM | Browse: 235 | Download: 225
Publication Name World Journal of Gastroenterology
Manuscript ID 46330
Country/Territory Japan
2019-02-10 08:29
Peer-Review Started
2019-02-12 01:23
To Make the First Decision
2019-03-20 06:32
Return for Revision
2019-03-20 08:09
2019-04-12 11:33
Second Decision
2019-04-28 09:33
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2019-04-29 10:21
Articles in Press
2019-04-29 10:21
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2019-05-16 00:37
Publish the Manuscript Online
2019-05-20 09:05
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access This is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology and Hepatology
Manuscript Type Prospective Study
Article Title Change in arterial tumor perfusion is an early biomarker of lenvatinib efficacy in patients with unresectable hepatocellular carcinoma
Manuscript Source Invited Manuscript
All Author List Hidekatsu Kuroda, Tamami Abe, Yudai Fujiwara, Takuya Okamoto, Miki Yonezawa, Hiroki Sato, Kei Endo, Takayoshi Oikawa, Kei Sawara and Yasuhiro Takikawa
Author(s) ORCID Number
Hidekatsu Kuroda http://orcid.org/0000-0002-1471-1087
Tamami Abe http://orcid.org/0000-0001-8314-7187
Yudai Fujiwara http://orcid.org/0000-0002-8436-5108
Takuya Okamoto http://orcid.org/0000-0002-8764-3951
Miki Yonezawa http://orcid.org/0000-0002-7509-7172
Hiroki Sato http://orcid.org/0000-0002-0258-5503
Kei Endo http://orcid.org/0000-0003-1020-7884
Takayoshi Oikawa http://orcid.org/0000-0002-1100-6980
Kei Sawara http://orcid.org/0000-0003-4608-277X
Yasuhiro Takikawa http://orcid.org/0000-0002-1729-1540
Funding Agency and Grant Number
Corresponding Author Hidekatsu Kuroda, MD, PhD, Doctor, Division of Hepatology, Department of Internal Medicine, Iwate Medical University, Uchimaru19-1, Morioka 020-8505, Iwate, Japan. hikuro@iwate-med.ac.jp
Key Words Hepatocellular carcinoma; Lenvatinib; Contrast-enhanced ultrasound; Time-intensity curve
Core Tip Lenvatinib is one of the first-line tyrosine kinase inhibitors used for unresectable hepatocellular carcinoma (HCC). In the present study, we evaluated the potential of early changes in the time-intensity curve (TIC) of arterial phase on contrast-enhanced ultrasound (CEUS) as early imaging biomarkers of lenvatinib efficacy. The rate of change for TIC parameters showed precisely reflect the therapeutic effects. CEUS may be useful for the early prediction of tumor response to lenvatinib therapy in patients with unresectable HCC.
Publish Date 2019-05-20 09:05
Citation Kuorda H , Abe T, Fujiwara Y, Okamoto T, Yonezawa M, Sato H, Endo K, Oikawa T, Sawara K, Takikawa Y. Change in arterial tumor perfusion is an early biomarker of lenvatinib efficacy in patients with unresectable hepatocellular carcinoma. World J Gastroenterol 2019; 25(19): 2365-2372
Url https://www.wjgnet.com/1007-9327/full/v25/i19/2365.htm
DOI https://dx.doi.org/10.3748/wjg.v25.i19.2365
Full Article (PDF) WJG-25-2365.pdf
Full Article (Word) WJG-25-2365.docx
Manuscript File 46330-Review.docx
Answering Reviewers 46330-Answering reviewers.pdf
Audio Core Tip 46330-Audio core tip.mp3
Biostatistics Review Certificate 46330-Biostatistics statement.pdf
Clinical Trial Registration Statement 46330-Clinical trial registration statement.pdf
Conflict-of-Interest Disclosure Form 46330-Conflict-of-interest statement.pdf
Copyright License Agreement 46330-Copyright license agreement.pdf
Signed Informed Consent Form(s) or Document(s) 46330-Informed consent statement.pdf
Institutional Review Board Approval Form or Document 46330-Institutional review board statement.pdf
Non-Native Speakers of English Editing Certificate 46330-Language certificate.pdf
Peer-review Report 46330-Peer-review(s).pdf
Scientific Misconduct Check 46330-Google-MA RY-1.png
Scientific Misconduct Check 46330-Google-MA RY-2.png
Scientific Misconduct Check 46330-Scientific misconduct check.pdf
Scientific Editor Work List 46330-Scientific editor work list.pdf